Developing new therapies for inflamatory diseases with Aquaporin technology

ApoGlyx develops first-in-class therapies based on aquaporin inhibitors.

Aquaporins are protein channels with broad importance in health and disease, ranging from maintaining the body’s fluid balance to roles in cancer, diabetes, malaria, inflammation, and autoimmunity. The human genome encodes thirteen related aquaporin isoforms, each with a specific expression pattern, and distinct substrate specificity

Recent news

ApoGlyx contributes to the United Nations 2030 Agenda for Sustainable Development

ApoGlyx closes 6 MSEK financing round

Supertrends experts provide insights on World Sepsis Day